Looking at the universe of stocks we cover at Dividend Channel, on 11/21/14, National Interstate Corp (NATL) will trade ex-dividend, for its quarterly dividend of $0.12, payable on 12/9/14. As a percentage of NATL's recent stock price of $28.80, this dividend works out to approximately 0.42%.Below is a dividend history chart for NATL, showing historical dividends prior to the most recent $0.12 declared by National Interstate Corp: In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from NATL is likely to continue, and whether the current estimated yield of 1.67% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of NATL shares, versus its 200 day moving average: Looking at the chart above, NATL's low point in its 52 week range is $21.18 per share, with $32.66 as the 52 week high point — that compares with a last trade of $28.80. In Wednesday trading, National Interstate Corp shares are currently trading flat on the day.
More from Stocks
La-Z-Boy Gets Moving After Analyst Upgrade of Furniture Maker
While noting the combination of China tariffs and recession fears may 'frighten some to the sidelines,' analysts at Raymond James cite the furniture maker's strong balance sheet with 'no funded debt,' rising dividends since 2013, and a still 'healthy U.S. consumer.'
Stocks Fall as Fed Chairman Vows to Continue Expansion but China Tariffs Bite
Stocks are falling Friday despite Federal Reserve Chairman Jerome Powell pledging to sustain the U.S. economic expansion as sentiment is dented by China saying it would take retaliatory measures in its tariff battle with the U.S.
Salesforce's Earnings and Guidance Aren't Quite as Impressive as They Look
Salesforce's Q2 performance was strong but its acquisitions muddy the year-over-year comparisons. Plus, its valuation gives its shares little margin for safety.
A Pair of Rare Disease Biotech Concerns Worth a Good Look
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.